We speculate that lymphoma B cells that have undergone metabolic rewiring are better fit than normal immune T cells in these conditions, and when combined with genetic lesions that favor antitumor immune escape (such as TNFRSF14 loss, CD70 gain, etc.)might lead to a situation highly advantageous for immune escape, but vulnerable to combination of metabolic and immunotherapies. This evidence concerns the gene CD70 and lymphoma.